LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the 2011 Citi Global Health Care Conference. The conference will take place March 1-3, 2011 at the Hilton Hotel in New York City, New York.
Stephen M. Simes, BioSante’s president & CEO, will speak Tuesday, March 1, 2011 at 2:30 pm EST. He will provide an overview of the company, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program. A live audio webcast of Mr. Simes’ remarks may be accessed at: http://www.veracast.com/webcasts/citigroup/healthcare2011/88112623.cfm. A webcast replay will be available one hour after conclusion of the presentation and will expire June 1, 2011.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.